| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| norethisterone | Tablet, uncoated | 350 microgram | Resolved | Available | Unexpected increase in consumer demand | 2/05/2025 |
| lidocaine hydrochloride monohydrate~adrenaline (epinephrine) acid tartrate | Injection, solution | 21.3 mg/mL~22.7 microgram/mL | Resolved | Available | Manufacturing | 2/05/2025 |
| sodium pertechnetate(99mTc) | Injection, solution | 18.5 GBq | Current | Unavailable | Manufacturing | 2/05/2025 |
| fluconazole | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Manufacturing | 2/05/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Anticipated | Available | Manufacturing | 2/05/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Current | Unavailable | Manufacturing | 2/05/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 2/05/2025 |
| metronidazole | Tablet, uncoated | 400 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| trimethoprim~sulfamethoxazole | Tablet, uncoated | 80 mg~400 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| finasteride | Tablet, film coated | 1 mg | Anticipated | Available | Manufacturing | 2/05/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 2/05/2025 |
| quetiapine fumarate | Tablet, modified release | 172.695 mg | Current | Limited Availability | Unexpected increase in consumer demand | 2/05/2025 |
| oxytocin | Injection, solution | 10 IU/mL | Current | Limited Availability | Manufacturing | 2/05/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 60 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| calcipotriol~betamethasone dipropionate | Ointment | 52.2 microgram/g~643 microgram/g | Current | Unavailable | Manufacturing | 2/05/2025 |
| imatinib mesilate | Capsule, hard | 119.47 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| tenofovir disoproxil maleate | Tablet, film coated | 300 mg | Resolved | Available | Manufacturing | 2/05/2025 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Current | Unavailable | Manufacturing | 2/05/2025 |
| busulfan | Injection, concentrated | 60 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~82.725 mg | Resolved | Available | Manufacturing | 2/05/2025 |
| dexmedetomidine hydrochloride | Injection, concentrated | 118 microgram/mL | Current | Limited Availability | Manufacturing | 2/05/2025 |
| ropivacaine hydrochloride | Injection, intravenous infusion | 2 mg/mL | Discontinued | Unavailable | Commercial Changes / Commercial viability | 2/05/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.376 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| olanzapine | Tablet, uncoated | 5 mg | Current | Unavailable | Manufacturing | 2/05/2025 |
| bortezomib | Injection, solution | 3.5 mg | Current | Limited Availability | Manufacturing | 2/05/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 113.37 mg~1000 mg | Current | Unavailable | Manufacturing | 2/05/2025 |
| metformin hydrochloride~sitagliptin hydrochloride monohydrate | Tablet, modified release | 1000 mg~56.685 mg | Current | Unavailable | Manufacturing | 2/05/2025 |
| fluorouracil | Cream | 50 mg/g | Current | Unavailable | Manufacturing | 2/05/2025 |
| rifampicin | Capsule, hard | 300 mg | Resolved | Available | Manufacturing | 2/05/2025 |
| norethisterone~ethinylestradiol | Tablet, uncoated | 500 microgram~36 microgram | Resolved | Available | Unexpected increase in consumer demand | 2/05/2025 |
| ethinylestradiol~norethisterone | Tablet, uncoated | 36 microgram~1 mg | Resolved | Available | Manufacturing | 2/05/2025 |
| sodium pertechnetate(99mTc) | Injection, solution | 20 GBq | Anticipated | Available | Manufacturing | 2/05/2025 |
| sodium pertechnetate(99mTc) | Injection | 370 GBq | Anticipated | Available | Manufacturing | 2/05/2025 |
| iopromide | Injection, solution | 498.72 mg/mL | Current | Unavailable | Manufacturing | 2/05/2025 |
| alprostadil | Injection, powder for | 20 microgram/mL | Current | Limited Availability | Unexpected increase in consumer demand | 2/05/2025 |
| alprostadil | Injection, powder for | 40 microgram/mL | Current | Unavailable | Manufacturing | 2/05/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 2/05/2025 |
| phenoxybenzamine hydrochloride | Capsule, hard | 10 mg | Current | Unavailable | Manufacturing | 1/05/2025 |
| midazolam | Injection, solution | 5 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| letrozole | Tablet, film coated | 2.5 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| Choriogonadotropin alfa | Injection, solution | 250 microgram | Current | Limited Availability | Unexpected increase in consumer demand | 1/05/2025 |
| perindopril erbumine | Tablet | 8 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| rizatriptan benzoate | Wafer | 14.53 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 1/05/2025 |
| esomeprazole | Capsule, enteric | 20 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| mercaptopurine monohydrate | Tablet | 50 mg | Current | Limited Availability | Manufacturing | 1/05/2025 |
| timolol maleate~dorzolamide hydrochloride | Eye Drops, solution | 6.83 mg/mL~22.26 mg/mL | Current | Limited Availability | Manufacturing | 1/05/2025 |
| metoprolol tartrate | Tablet, uncoated | 50 mg | Anticipated | Available | Manufacturing | 1/05/2025 |
| valsartan~sacubitril | Tablet, film coated | 51.4 mg~48.6 mg | Current | Unavailable | Manufacturing | 1/05/2025 |
| sacubitril~valsartan | Tablet, film coated | 24.3 mg~25.7 mg | Current | Unavailable | Manufacturing | 1/05/2025 |
| valsartan~sacubitril | Tablet, film coated | 102.8 mg~97.2 mg | Current | Unavailable | Manufacturing | 1/05/2025 |
| ropivacaine hydrochloride | Injection, solution | 2 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 1/05/2025 |
| losartan potassium | Tablet, film coated | 50 mg | Current | Unavailable | Unexpected increase in consumer demand | 1/05/2025 |
| spironolactone | Tablet, film coated | 100 mg | Anticipated | Available | Manufacturing | 1/05/2025 |
| Tiger snake antivenom | Injection, concentrated | 3000 U | Anticipated | Available | Manufacturing | 1/05/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 30/04/2025 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 6.935 mg~80 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~13.87 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 80 mg~13.87 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| rocuronium bromide | Injection, solution | 50 mg | Resolved | Available | Manufacturing | 30/04/2025 |
| oxazepam | Tablet, uncoated | 15 mg | Current | Unavailable | Manufacturing | 30/04/2025 |
| trandolapril | Capsule, hard | 1 mg | Current | Unavailable | Manufacturing | 30/04/2025 |
| trandolapril | Capsule, hard | 2 mg | Current | Unavailable | Manufacturing | 30/04/2025 |
| trandolapril | Capsule, hard | 4 mg | Current | Unavailable | Manufacturing | 30/04/2025 |
| olmesartan medoxomil~hydrochlorothiazide~amlodipine besilate | Tablet | 40 mg~12.5 mg~6.944 mg | Resolved | Available | Manufacturing | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 40 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| amlodipine besilate~telmisartan | Tablet, multilayer | 13.87 mg~40 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 80 mg~6.935 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| telmisartan~amlodipine besilate | Tablet, multilayer | 80 mg~13.87 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 30/04/2025 |
| capecitabine | Tablet, film coated | 500 mg | Current | Limited Availability | Unexpected increase in consumer demand | 30/04/2025 |
| prilocaine hydrochloride~felypressin | Injection, solution | 30 mg/mL~.54 microgram/mL | Resolved | Available | Manufacturing | 30/04/2025 |
| bosentan monohydrate | Tablet, film coated | 129.08 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 40 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 20 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 30 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 10 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, hard | 60 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| oxazepam | Tablet, uncoated | 30 mg | Current | Unavailable | Manufacturing | 30/04/2025 |
| carboplatin | Injection, solution | 10 mg/mL | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 30/04/2025 |
| midazolam | Injection, solution | 1 mg/mL | Anticipated | Available | Unexpected increase in consumer demand | 30/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 40 mg | Current | Limited Availability | Manufacturing | 30/04/2025 |
| gentamicin | Injection, solution | 80 mg | Resolved | Available | Manufacturing | 29/04/2025 |
| isosorbide dinitrate | Tablet, uncoated | 5 mg | Anticipated | Available | Manufacturing | 29/04/2025 |
| donepezil hydrochloride | Tablet, film coated | 10 mg | Resolved | Available | Manufacturing | 29/04/2025 |
| exemestane | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 29/04/2025 |
| propofol | Injection, emulsion | 10 g/L | Current | Limited Availability | Transport / Logistic issues / Storage capacity issues | 29/04/2025 |
| procarbazine hydrochloride | Capsule, hard | 58.3 mg | Anticipated | Available | Manufacturing | 29/04/2025 |
| mupirocin | Ointment | 20 mg/g | Current | Limited Availability | Unexpected increase in consumer demand | 29/04/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Limited Availability | Unexpected increase in consumer demand | 29/04/2025 |
| atorvastatin calcium trihydrate~ezetimibe | Tablet, film coated | 20.681 mg~10 mg | Current | Unavailable | Manufacturing | 29/04/2025 |
| ezetimibe~atorvastatin calcium trihydrate | Tablet, film coated | 10 mg~10.341 mg | Current | Unavailable | Manufacturing | 29/04/2025 |
| deferasirox | Tablet, film coated | 90 mg | Anticipated | Available | Manufacturing | 29/04/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 10.844 mg | Resolved | Available | Manufacturing | 29/04/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.688 mg | Resolved | Available | Manufacturing | 29/04/2025 |
| trimethoprim | Tablet, uncoated | 300 mg | Current | Limited Availability | Manufacturing | 29/04/2025 |
| clopidogrel hydrogen sulfate | Tablet, film coated | 97.875 mg | Current | Unavailable | Manufacturing | 29/04/2025 |
| naproxen | Tablet, uncoated | 250 mg | Current | Limited Availability | Manufacturing | 29/04/2025 |
| dutasteride~tamsulosin hydrochloride | Capsule, modified release | 500 microgram~400 microgram | Current | Unavailable | Manufacturing | 29/04/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | .77 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/04/2025 |
| estradiol hemihydrate | Drug delivery system, transdermal | 3.09 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 29/04/2025 |
| methylphenidate hydrochloride | Tablet, uncoated | 10 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 28/04/2025 |
| valaciclovir | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 28/04/2025 |
| fentanyl | Drug delivery system, transdermal | 12.6 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| sulfamethoxazole~trimethoprim | Tablet | 800 mg~160 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/04/2025 |
| sulfamethoxazole~trimethoprim | Tablet, uncoated | 800 mg~160 mg | Current | Limited Availability | Manufacturing | 28/04/2025 |
| candesartan cilexetil | Tablet, uncoated | 4 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| carboplatin | Injection, solution | 450 mg | Anticipated | Available | Manufacturing | 28/04/2025 |
| olmesartan medoxomil | Tablet, film coated | 40 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| solifenacin succinate | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 28/04/2025 |
| solifenacin succinate | Tablet, film coated | 10 mg | Current | Unavailable | Manufacturing | 28/04/2025 |
| lacosamide | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 28/04/2025 |
| pregabalin | Capsule, hard | 25 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| prasugrel | Tablet, film coated | 5 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| montelukast sodium | Tablet, film coated | 10.4 mg | Current | Limited Availability | Manufacturing | 28/04/2025 |
| levothyroxine sodium | Tablet | .05 mg | Resolved | Available | Manufacturing | 28/04/2025 |
| levothyroxine sodium | Tablet | .1 mg | Current | Limited Availability | Manufacturing | 28/04/2025 |
| Fremanezumab | Injection, solution | 225 mg | Current | Limited Availability | Unexpected increase in consumer demand | 28/04/2025 |
| reboxetine mesilate | Tablet, uncoated | 5.224 mg | Anticipated | Available | Manufacturing | 28/04/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Anticipated | Available | Manufacturing | 28/04/2025 |
2025年5月5日